Akebia Therapeutics, Inc 8-K, filed Jun 9, 2020
Akebia Therapeutics, Inc. (AKBA)
About this 8-K
Akebia Therapeutics, Inc filed this 8-K on June 9, 2020, reporting on events of June 5, 2020.
Items reported
- Item 3.03: Change to shareholders' rights
- Item 5.07: Shareholder vote results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| |
|
| ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
| |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
| |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.03. Material Modification to Rights of Security Holders.
On June 5, 2020, Akebia Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Ninth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock, par value $0.00001 per share (“Common Stock”), from 175,000,000 to 350,000,000. As referenced below, the Company’s stockholders approved the Certificate of Amendment at the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) held on June 5, 2020. The Company’s Board of Directors (the “Board”) had previously approved the Certificate of Amendment, subject to stockholder approval.
The foregoing description of the Certificate of Amendment is a summary only and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 hereto.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting on June 5, 2020. The stockholders (i) elected three Class III directors to the Board to serve until the 2023 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal; (ii) approved the Certificate of Amendment to increase the number of authorized shares of Common Stock from 175,000,000 to 350,000,000; (iii) approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers; (iv) approved, on a non-binding, advisory basis, an annual advisory vote on executive compensation; and (v) ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.
(i) The Class III directors elected to the Board, as well as the number of votes for, votes withheld and broker non-votes with respect to each of these individuals, are set forth below:
| Director |
Votes For |
Votes Withheld |
Broker Non-Votes |
|||||||||
| Adrian Adams |
79,418,501 |
11,551,241 |
20,223,043 |
|||||||||
| Maxine Gowen, Ph.D. |
79,501,369 |
11,468,373 |
20,223,043 |
|||||||||
| Michael Rogers |
79,876,241 |
11,093,501 |
20,223,043 |
|||||||||
(ii) The proposal to approve the Certificate of Amendment to increase the number of authorized shares of Common Stock from 175,000,000 to 350,000,000 received the following votes:
| Votes For: |
104,285,773 |
|||
| Votes Against: |
6,744,093 |
|||
| Abstentions: |
162,919 |
(iii) The advisory vote on executive compensation received the following votes:
| Votes For: |
86,399,013 |
|||
| Votes Against: |
4,185,752 |
|||
| Abstentions: |
384,977 |
|||
| Broker Non-Votes |
20,223,043 |
(iv) The advisory vote on the frequency of the advisory vote on executive compensation received the following votes:
| 1 Year: |
88,333,537 |
|||
| 2 Years: |
186,734 |
|||
| 3 Years: |
2,102,430 |
| Abstentions: |
347,041 |
|||
| Broker Non-Votes |
20,223,043 |
Based on the results of the vote, and consistent with the Board’s recommendation to stockholders, the Board has determined to hold a non-binding advisory vote on executive compensation annually until the next required non-binding advisory vote on the frequency of holding future votes regarding the compensation of the Company’s named executive officers.
(v) The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 received the following votes:
| Votes For: |
107,855,430 |
|||
| Votes Against: |
469,237 |
|||
| Abstentions: |
2,868,118 |
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit |
Description | |||
| 3.1 |
||||
| 104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AKEBIA THERAPEUTICS, INC. | ||||||
| Date: June 9, 2020 |
By: |
/s/ John P. Butler | ||||
| Name: |
John P. Butler | |||||
| Title: |
President and Chief Executive Officer |
Exhibit 3.1
CERTIFICATE OF AMENDMENT
OF
NINTH RESTATED CERTIFICATE OF INCORPORATION
OF
AKEBIA THERAPEUTICS, INC.
Akebia Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:
FIRST: That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated Certificate of Incorporation of the Corporation to increase the number of authorized shares of Common Stock of the Corporation.
SECOND: That the amendment to the Restated Certificate of Incorporation of the Corporation set forth in this Certificate of Amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of Delaware by the Board of Directors and holders of a majority of the outstanding stock of the Corporation entitled to vote thereon.
THIRD: That upon the effectiveness of this Certificate of Amendment, Section (a) of Article FOURTH of the Restated Certificate of Incorporation is hereby amended and restated as follows:
“(a) Authorized Shares. The total number of shares of stock which the Corporation shall have authority to issue is 375,000,000, consisting of (i) 350,000,000 shares of Common stock, par value $0.00001 per share (“Common Stock”), and (ii) 25,000,000 shares of Preferred Stock, par value $0.00001 per share (“Preferred Stock”). Such stock may be issued from time to time by the Corporation for such consideration as may be fixed by the board of directors of the Corporation (the “Board of Directors”).”
IN WITNESS WHEREOF, this Certificate of Amendment of Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 5th day of June, 2020.
| /s/ John P. Butler | ||
| By: | John P. Butler | |
| Title: | President and Chief Executive Officer |